Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Leboeuf

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Blood Cancer Journal|November 5, 2020
Correction: Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patientsS Thiant, M M Moutuou, P Laflamme, et al.
Thrombosis and Haemostasis|March 28, 2002
Expression of coagulation factor IX in a haematopoietic cell lineM H Rodriguez, N Enjolras, J L Plantier, et al.
Blood Cancer Journal|April 8, 2017
Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patientsS Thiant, M M Moutuou, P Laflamme, et al.
Scientific Reports|March 10, 2019
Induction of tumor-specific CTL responses using the C-terminal fragment of Viral protein R as cell penetrating peptideD A Gross, C Leborgne, P Chappert, et al.
Annales Pharmaceutiques Francaises|January 1, 1978
[alpha-Acyl indole type alkaloids: study of their antiviral and local anesthetic properties (author's transl)]M J Hoizey, L Le Men-Olivier, J Le Men, et al.
Mucosal Immunology|May 9, 2013
Interleukin-22 binding protein (IL-22BP) is constitutively expressed by a subset of conventional dendritic cells and is strongly induced by retinoic acidJ C J Martin, G Bériou, M Heslan, et al.
The American Journal of Cardiology|April 15, 1996
A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II InvestigatorsC M O'Connor, R B Meese, S McNulty, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Blood Cancer Journal|November 5, 2020
Correction: Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patientsS Thiant, M M Moutuou, P Laflamme, et al.
Thrombosis and Haemostasis|March 28, 2002
Expression of coagulation factor IX in a haematopoietic cell lineM H Rodriguez, N Enjolras, J L Plantier, et al.
Blood Cancer Journal|April 8, 2017
Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patientsS Thiant, M M Moutuou, P Laflamme, et al.
Scientific Reports|March 10, 2019
Induction of tumor-specific CTL responses using the C-terminal fragment of Viral protein R as cell penetrating peptideD A Gross, C Leborgne, P Chappert, et al.
Annales Pharmaceutiques Francaises|January 1, 1978
[alpha-Acyl indole type alkaloids: study of their antiviral and local anesthetic properties (author's transl)]M J Hoizey, L Le Men-Olivier, J Le Men, et al.
Mucosal Immunology|May 9, 2013
Interleukin-22 binding protein (IL-22BP) is constitutively expressed by a subset of conventional dendritic cells and is strongly induced by retinoic acidJ C J Martin, G Bériou, M Heslan, et al.
The American Journal of Cardiology|April 15, 1996
A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II InvestigatorsC M O'Connor, R B Meese, S McNulty, et al.
Pageof 3